Compare CVS Health Corp (CVS) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Xylem, Inc. — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Xylem, Inc. trades at $102.3 (market cap $23.77B). The key difference: CVS Health Corp is far larger — about 4.7× Xylem, Inc.'s market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Xylem, Inc. for 50 Days on average.
| CVS | XYL | |
|---|---|---|
Market Cap | $112.49B | $23.77B |
Volume | 8,467,392 | 2,477,250 |
Sector | Health | Industrials |
52-Week High | $110.60 | $152.95 |
52-Week Low | $70.08 | $100.92 |
Typical Hold Time | 83 Days | 50 Days |
Enterprise Value | $174.83B | $25.55B |
Dividend Yield | 3.02% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Xylem (XYL) trades at $101.99, down 2.48% today, amid bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 27. Revenue grew from $5.5B in 2022 to $9.04B in 2025, while net income margin expanded to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen industrial presence.
Outlook remains positive with 47.5% analyst buy ratings and $149.13 consensus price target, representing 46% upside. Key risks include China weakness and higher debt from recent note offerings. The stock offers value with P/E of 24.24 and consistent dividend payments, though technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
